NCT06755086

TF-antigen Targeting Molecular Probe for PET Imaging in Solid Tumors

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 20 (estimated)
• Sponsor: Peking University Cancer Hospital & Institute · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The objective of the study is to construct a noninvasive approach using 124I-labeled monoclonal antibody radiotracer to detect the Thomsen-Friedenreich antigen (TF-antigen, CD176) expression of tumor lesions in patients with solid tumors and to identify patients benefiting from TF-antigen targeting treatment.

Detailed description

Analysis plan: 1. Recruit 3-5 participants to analyze preliminary pharmacokinetic/first-in-human dose (FIH), major organ distribution, and tumor uptake information via whole-body PET/CT imaging; 2. Recruit 20 participants to analyze in vivo safety and tumor targeting information; 3. Recruit all participants for a final summary.

Conditions

• Solid Tumors

Interventions

Type	Name	Description
DRUG	18-FDG	All study participants will undergo one 18F-FDG PET/ CT scan.

Timeline

• Start date: 2025-01-06
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2025-01-01
• Last updated: 2025-01-01

Locations

1 site across 1 country: China